Radioimmunotherapy With Tositumomab and Iodine-131 Tositumomab for Low-Grade Non-Hodgkin Lymphoma: Nursing Implications

Judith M. Estes

Kathleen J. Clapp

ONF 2004, 31(6), 1119-1126. DOI: 10.1188/04.ONF.1119-1126

Purpose/Objectives: To review radioimmunotherapy approaches for low-grade non-Hodgkin lymphoma (NHL) with a focus on tositumomab and iodine-131 tositumomab (Bexxar®, Corixa Corporation, Seattle, WA, and GlaxoSmithKline, Philadelphia, PA). Nursing implications for Bexxar therapy are reviewed, including radiation safety, patient education, and the management of therapy-related toxicities.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.